Revive Therapeutics (OTC:RVVTF) said today that it inked a research agreement with the University of Wisconsin-Madison to develop a drug delivery technology for cannibinoids.
The research program, led by Jess Reed, is slated to evaluate chitosan-tannin composite biomaterial as a delivery mechanism for cannabinoids. Therapeutic biomaterials made from a composite of chitosan and tannin include nanoparticles, hydrogels, bio-foams, bio-gels or a liposomal coating.
“We are very excited to advance a novel cannabinoid-focused drug delivery technology with the potential to safely and effectively treat, but not limited to, pain, inflammatory skin disorders, and liver diseases,” Revive CEO Craig Leon said in prepared remarks. “We are focused on continuing to build our cannabinoid-based product pipeline and our expansion in cannabinoid-based drug delivery reinforces our commitment to this strategy. Our research relationship with the University of Wisconsin-Madison builds upon our efforts to lead the way in providing novel cannabinoid-based therapies for serious and unmet medical needs.”
“I am very excited about the potential and the initiation of the development of a novel ground-breaking cannabinoid-focused drug delivery technology,” Jess Reed, professor of animal sciences, added. “The opportunities of the drug delivery technology and cannabinoids are plentiful and I look forward to validating the true potential of the drug delivery technology in allowing novel ways to deliver cannabinoids for various diseases.”
